Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1995-04-17
1998-07-28
Nazario-Gonzalez, Porfirio
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514211, A61K 31545, A61K 3147
Patent
active
057863440
ABSTRACT:
This invention provides methods and combination formulations and kits to reduce the toxicity of camptothecin drugs, such as irinotecan (CPT-11). Disclosed are therapeutics and treatment methods employing such drugs in combination with agents that increase conjugative enzyme activity or glucuronosyltransferase activity, and agents that decrease biliary transport protein activity, such as cyclosporine A, the resultant effects of which are to decrease the significant side effects previously associated with treatment using these drugs.
REFERENCES:
Ansher et al., "Chemoprotective Effects of Two Dithiolthiones and of Butylhydroxyanisole Against Carbon Tetrachloride and Acetaminophen Toxicity," Hepatology, 3(6):932-935, 1983.
Araki et al., Relationship Between Development of Diarrhea and the Concentration of SN-38, an Active Metabolite of CPT-11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT-11, Jpn. J. Cancer Res., 84:697-702, 1993.
Atsumi et al., "Identification of the Metabolites of Irinotecan, a New Derivative of Camptothecin, in Rat Bile and its Biliary Excretion," Xenobiotica, 21(9):1159-1169, 1991.
Boiteux-Antoine et al., "Comparative Induction of Drug-Metabolizing Enzymes by Hypolipidaemic Compounds," Gen. Pharmac., 20(4):407-412, 1989.
Burger et al., "Pharmacokinetic Interaction Between Rifampin and Zidovudine," Antimicrobial Agents and Chemotherapy, 37(7):1426-1431, 1993.
Davies and Schnell, "Oltipraz-Induced Amelioration of Acetaminophen Hepatotoxicity in Hamsters," Toxicology and Applied Pharmacology, 109:29-40, 1991.
De Morais et al., "Biotransformation and Toxicity of Acetaminophen in Congenic RHA Rats with or without a Hereditary Deficiency in Bilirubin UDP-Glucuronosyltransferase," Toxicology and Applied Pharmacology, 117:81-87, 1992.
Egner et al., "Regulation of Phase 2 Enzyme Induction by Oltipraz and other Dithiolethiones," Carcinogenesis, 15(2):177-181, 1994.
Fournel et al., "Structure-dependent induction of bilirubin glucuronidation and lauric acid 12-hydroxylation by arylcarboxylic acids chemically related to clofibrate," Biochimica et Biophysica Acta, 842:202-213, 1985.
Hecht et al., "4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide, metabolites of a tobacco-specific lung carcinogen, in the urine of black and white smokers," Proceedings of the American Association for Cancer Research, 35:1702, 1994.
Hjelle, Jerry J., "Hepatic UDP-Glucuronic Acid Regulation during Acetaminophen Biotransformation in Rats," The Journal of Pharmacology and Experimental Therapeutics, 237(3):750-756, 1986.
Lubet et al., "A Pleiotropic Response to Phenobarbital-Type Enzyme Inducers in the F344/NCr RAT," Chemical Pharmacology, 43(5):1067-1078, 1992.
Magdalou et al., "Peroxisome Proliferators as Inducers and Substrates of UDP-glucuronosyltransferases," Biol. Cell., 77:13-16, 1993.
Manning and Franklin, "Induction of rat UDP-glucuronosyltransferase and glutathione S-transferase activities by L-buthionine-S,R-sulfoximine without induction of cytochrome P-450," Toxicology, 65:149-159, 1990.
Negoro et al., "Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer," Journal of the National Cancer Institute, 83(16):1164-1168, 1991.
Ohe et al., "Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion," Journal of the National Cancer Institute, 84(12):972-974, 1992.
Prochaska and Fernandes, "Elevation of serum Phase II enzymes by anticarcinogenic enzyme inducers: markers for a chemoprotected state?," Carcinogenesis, 14(12):2441-2445, 1993.
Rothenberg et al., "Phase I and Pharmacokinetic Trial of Weekly CPT-11," Journal of Clinical Oncology, 11(11):2194-2204, 1993.
Rowinsky et al., "Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor Administered as a Ninety-Minute Infusion Every 3 Weeks," Cancer Research, 54:427-436, 1994.
Charuk et al., "Interaction of Rat Kidney P-Glycoprotein with a Urinary Component and Various Drugs Including Cyclosporin A," Am. J. Physiol., 266:F66-F75, 1994.
De Lannoy et al., "Cyclosporin and Quinidine Inhibition of Renal Digoxin Excretion: Evidence for Luminal Secretion of Digoxin," Am. J. Physiol, 263:F613-F622, 1992.
Dhainaut et al., "New Triazine Derivatives as Potent Modulators of Multidrug Resistance," J. Med. Chem., 35:2481-2496, 1992.
Gupta et al., "Metabolic Fate of Irinotecan in Humans: Correltaion of Glucuronidation with Diarrhea," Cancer Research, 54:3723-3725, Jul. 1994.
Hait et al., "Terfenadine (Seldane.RTM.): A New Drug for Restoring Sensitivity to Multidrug Resistant Cancer Cells," Biochemical Pharmacology, 45(2):401-406, 1993.
Hendricks et al., "Effect of P-Glycoprotein Expression on the Accumulation and Cytotoxicity of Topotecan (SK&F 104864), a New Campotthecin Analogue," Cancer Research, 52:2268-2278, Apr. 1992.
Michelson and Slate, "A Mathematical Model for the Inhibition of the Multidrug Resistance-Associated P-Glycoprotein Pump," Bulletin of Mathematical Biology, 56(2):207-223, 1994.
Narita et al., "Inhibition of Beta-Glucuronidase by Natural Glucuronides of Kampo Medicines Using Glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a Substrate," Xenobiotica, 23(1):5-10, Jan. 1993.
Ohi et al., "Intravesical Instillation of Adriamycin in the Prescence or Absence of Verapamil for the Treatment of Superficial Bladder Cancer: Preliminary Report of a Collaborative Study," Cancer Chemother. Pharmacol., 30:S50-S54, 1992.
Perez et al., "Mechanisms and Modulation of Resistance to Chemotherapy in Ovarian Cancer," Cancer Supplement, 71(4):1571-1580, Feb. 1993.
Saeki et al., "Human P-Glycoprotein Transports Cyclosporin A and FK506," The Journal of Biological Chemistry, 268(9):6077-6080, 1993.
Sakata et al., "Preventive Effect of TJ-14, a Kampo (Chinese herb) Medicine, on Diarrhea Induced by Irinotecan Hydrochloride (CPT-11)," Gan-To-Kagaku-Ryoho, 21(8):1241-4, Jul. 1994; Abstract only.
Slichenmyer et al., "The Current Status of Camptothecin Analogues as Antitumor Agents," Journal of the National Cancer Institute, 85(4):271-291, Feb. 1993.
Slichenmyer et al., "Camptothecin Analogues: Studies from The Johns Hopkins Oncology Center," Cancer Chemother. Pharmacol., 34:S53-S57, 1994.
Watanabe et al., "Kinetic Analysis of Hepatobiliary Transport of Vincristine in Perfused," Journal of Hepatology, 16:77-88, 1992.
Zacherl et al., "Inhibition of P-Glycoprotein-Mediated Vinblastine Transport Across HCT-8 Intestinal Carcinoma Monolayers by Verapamil Cyclosporine A and SDZ PSC 833 in Dependece on Extracellular pH," Cancer Chemother. Pharmcol., 34:125-132, 1994.
Bertrand et al., "Sequential Administration of Camptothecin and Etoposide Circumvents the Antagonistic Cytotoxicity of Simultaneous Drug administration in Slowly Growing Human Colon Carcinoma HT-29 Cells," Eur. J. Cancer, 28A(4-5):743-748, 1992.
Kano et al., "Effects of CPT-11 in Combination with Other Anti-Cancer Agents in Culture," Int. J. Cancer, 50(4):604-610, 1992.
Karato et al., "Phase I Study of CPT-11 and Etoposide in Patients with Refractory Solid Tumors," J. Clin. Oncol., 11(10):2030-2035, Oct. 1993.
Kaufmann, "Antagonism Between Camptothecin and Topoisomerase II-Directed Chemotherapeutic Agents in a Human Leukemia Cell Line," Cancer Res., 51(4):1129-1136, Feb. 1991.
Rowinsky et al., "Taxcol: Pharmacology, Metabolism and Clinical Implications," Cancer Surv., 17:283-304, 1993.
Taudou et al., "Inhibition of DNA Synthesis and DNA Fragmentation in Stimulated Splenocytes by the Concentrated Action of Topoisomerase I and II Poisons," Biochem. Pharmacol., 45(2):331-337, 1993.
Zhang et al., "Inhibitory Effects of Homoharringtonine and Hydroxycamptothecin in Combination with Other Agents on Cancer Cell Growth," Asia Pac. J. Pharmacol., 7:191-195, 1992.
PCT Search Report dated Jul. 5, 1995.
Cordon-Cardo et al., "Expression of the multidrug resistant gene product (P-glycoprotein) in human normal and tumor tissues," J. Histochem. Cytochem., 38:1277-1287, 1990.
de Forni et al., "Phase I and pharmacokinetic
Gupta Elora
Ratain Mark J.
ARCH Development Corporation
Nazario-Gonzalez Porfirio
LandOfFree
Camptothecin drug combinations and methods with reduced side eff does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Camptothecin drug combinations and methods with reduced side eff, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Camptothecin drug combinations and methods with reduced side eff will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-23726